In the memory-clinic-based Amsterdam Dementia Cohort study, baseline CSF neurogranin levels were greater in patients with mild cognitive impairment who progressed to Alzheimer’s disease and were prognostic of progress from mild cognitive impairment to Alzheimer’s disease [263]. Here, NRGN is linked to early-onset autosomal dominant Alzheimer disease.